| Original language | English (US) |
|---|---|
| Pages (from-to) | 2719-2721 |
| Number of pages | 3 |
| Journal | The Lancet |
| Volume | 388 |
| Issue number | 10061 |
| DOIs |
|
| State | Published - Dec 3 2016 |
Bibliographical note
Funding Information:NEB is funded by the National Institutes of Health Early Independence Award from the Office of the Director ( 1DP5OD009162 ). NEB has collaborated with Ray Borrow and co-authored studies of meningococcal A and B vaccines using data from the USA and Africa. HC is funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in evaluation of interventions at the University of Bristol in partnership with Public Health England (PHE). HC has collaborated with PHE when developing mathematical and economic models predicting the impact of 4CMenB in the UK and has co-authored papers with PHE colleagues, including Article authors Shamez Ladhani, Helen Campbell, Ray Borrow, and Mary Ramsay, on preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using Bexsero, but she had no involvement in the present Article. HC has received honoraria from Sanofi Pasteur, paid to her employer, and consultancy fees from IMS Health and AstraZeneca. The views expressed are those of the author(s) and not necessarily those of the NIH, NHS, the NIHR, the Department of Health, or Public Health England.